Calycosin Alleviates Oxidative Stress and Pyroptosis Induced by High Glucose in Human Retinal Capillary Endothelial Cells Induced by High Glucose

被引:2
|
作者
Wang, Juan [1 ]
Zhang, Jianyong [1 ]
Zhao, Yan [1 ]
机构
[1] Guizhou Prov Peoples Hosp, Dept Ophthalmol, Guiyang, Guizhou, Peoples R China
关键词
Calycosin; Diabetic retinopathy; HMGB1/NF-kappa B pathway; Oxidative stress; Pyroptosis; NF-KAPPA-B; DIABETIC-RETINOPATHY; INFLAMMATION; ACTIVATION; APOPTOSIS; PATHWAY; TYPE-1; FAMILY; DRUGS;
D O I
10.37290/ctnr2641-452X.21:40-46
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Calycosin is an isoflavone isolated from the roots of Astragalus membranaceus. Due to its antioxidant and anti-inflammatory activities, it has been extensively used in traditional Chinese medicine formulations. Herein, we have evaluated the mechanism of action of calycosin using high glucose induced HRCEC cells as a model. The observed effects of calycosin include alleviation of oxidative stress induced by high glucose through promotion of SOD, GSH-Px and inhibition of ROS expression. Moreover, calycosin relieved HG-induced inflammation and pyroptosis by upregulating IL-1 beta, IL-18 and downregulating NLRP3, ASC, and cleaving caspase-1/procaspase-1. Calycosin also inhibited HMGB1/NF-kappa B pathway activation by promoting p-P65/P65, p-I kappa B alpha, HMGB1 and decreasing I.Ba. All of these results support the notion that calycosin alleviates oxidative stress and pyroptosis of HRCEC cells induced by high glucose by inhibiting activation of the HMGB1/ NF-kappa B pathway.
引用
收藏
页码:40 / 46
页数:7
相关论文
共 50 条
  • [11] Sequoyitol Alleviates High Glucose-Induced Inflammation, Oxidative Stress and Apoptosis of Retina Epithelial Cells
    Hu, Liping
    Zhang, Rui
    Wu, Jianhua
    Feng, Chao
    Kong, Li
    JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING, 2021, 11 (05) : 1003 - 1009
  • [12] Dihydromyricetin Alleviates High Glucose-Induced Oxidative Stress and Apoptosis in Human Retinal Pigment Epithelial Cells by Downregulating miR-34a Expression
    Li, Wenjun
    Xiao, Hongxia
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 387 - 397
  • [13] Celastrol inhibits the proliferation and angiogenesis of high glucose-induced human retinal endothelial cells
    Jian Fang
    Xiaoke Chang
    BioMedical Engineering OnLine, 20
  • [14] Celastrol inhibits the proliferation and angiogenesis of high glucose-induced human retinal endothelial cells
    Fang, Jian
    Chang, Xiaoke
    BIOMEDICAL ENGINEERING ONLINE, 2021, 20 (01)
  • [15] Fluorometholone inhibits high glucose-induced cellular senescence in human retinal endothelial cells
    Zhou, Xuemei
    Wang, Lifeng
    Zhang, Zhongwei
    Liu, Jing
    Qu, Qun
    Zu, Yuanyuan
    Shi, Dejing
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2022, 41
  • [16] Fluorometholone inhibits high glucose-induced cellular senescence in human retinal endothelial cells
    Zhou, Xuemei
    Wang, Lifeng
    Zhang, Zhongwei
    Liu, Jing
    Qu, Qun
    Zu, Yuanyuan
    Shi, Dejing
    HUMAN & EXPERIMENTAL TOXICOLOGY, 2022, 41
  • [17] Protective Effects of Panax notoginseng Saponins against High Glucose-Induced Oxidative Injury in Rat Retinal Capillary Endothelial Cells
    Fan, Yue
    Qiao, Yuan
    Huang, Jianmei
    Tang, Minke
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2016, 2016
  • [18] Antioxidant and Anti-Inflammatory Effects of Blueberry Anthocyanins on High Glucose-Induced Human Retinal Capillary Endothelial Cells
    Huang, Wuyang
    Yan, Zheng
    Li, Dajing
    Ma, Yanhong
    Zhou, Jianzhong
    Sui, Zhongquan
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2018, 2018
  • [19] Prohibitin inhibits high glucose-induced apoptosis via maintaining mitochondrial function in human retinal capillary endothelial cells
    Zhang, Li
    He, Ying
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 23 (06)
  • [20] Melatonin Alleviates High Glucose-induced Oxidative Stress and Mitochondrial Dysfunction in Chondrocytes
    Mehrzadi, Saeed
    Hassani, Shokoufeh
    Hosseinzadeh, Azam
    CURRENT DRUG THERAPY, 2024, 19 (06) : 719 - 726